Ayesha Alvero, MD, MSc

Professor, Department of Obstetrics and Gynecology, Wayne State University; Member Molecular Therapeutics Group, Barbara Ann Karmanos Cancer Institute

Dr. Alvero received her M.D. from the University of the East, Manila, Philippines and her M.Sc. in Cellular and Molecular Biology from the University of New Haven, West Haven, CT. Her first post- doctoral fellowship was in the laboratory of Dr. Barry Kacinski in the Department of Therapeutic Radiology at Yale University School of Medicine. Afterwards, she joined Dr. Gil Mor’s laboratory at the Department of Obstetrics, Gynecology, and Reproductive Sciences also at Yale for a second post-doctoral fellowship and focused her work in ovarian cancer. Dr. Alvero’s research is in the elucidation of mechanisms that support recurrent ovarian cancer such as those that promote inherent and acquired chemoresistance as well as mechanisms that support tumor repair and metastatic potential.

• Paper accepted April 17, 2020 in the journal Oncoimmunology: “Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer” by Ayesha B. Alvero, Douglas Hanlon, Mary Pitruzzello, Renata Filler, Eve Robinson, Olga Sobolev, Roslyn Tedja, Alessandra Ventura, Patrick Han, Marcus Bosenberg, Richard Edelson, and Gil Mor.
• Paper accepted March 5, 2020 in the journal Oncogene: “CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential” by Juanni Li, Ayesha B. Alvero, Sudhakar Nut, Roslyn Tedja, Cai Roberts, Mary Pitruzzello, Yimin Li, Qing Xiao, Sai Zhang, Yaqi Gan, Xiaoying Wu, Gil Mor, and Gang Yin.

1. Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Edelson R, Mor G.  Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology, 2020.

2. Li J, Alvero AB, Nuti S, Tedja R, Roberts CM, Pitruzzello M, Li Y, Xiao Q, Zhang S, Gan Y, Wu X, Mor G, Yin G. CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene, 2020.

3. Tedja R. Roberts C. Alvero AB, Cardenas C. Yang-Hartwich Y, Spadinger S, Pitruzzello M, Yin, G, Glackin CA,  and Mor G. Phosphorylation of Twist1 Serine144 by protein kinase C aplha contribute to its stable expression. Journal of Biological Chemistry, 2019; 294(13):5082-5093.

4. Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurrea-Soteras M, Sumi N, Alvero AB, Glackin C, and Mor G. p53-Pirh2 complex promotes Twist1 degradation and inhibits EMT in ovarian cancer cells. Mol Cancer Res, 2019; 17(1):153-164.

5. Alvero AB, Kim D, Lima E, Sumi NJ, Lee JS, Cardenas C, Pitruzzello M, Silasi DA, Buza N, Fahmy T, Mor G. Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. Sci Rep, 2017; 7:40989.

6. Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G, Alvero AB. Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells. Apoptosis, 2017; 22(4):558-569.

7. Mor G, Aldo PB, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunology, 2017 Aug;17(8):469-482

8. Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, Guo K, Zhou W, Wang Y, Liu J, Zhang Y, Mor G, Wen J, Yin G. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget, 2016; 7(49):80633-80654.

9. Cardenas C, Alvero AB, Yun BS, Mor G. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer, 2016 Sep;23(9):R411-22.

10. Alvero AB, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, Cardenas C, Steinmacher S, Silasi DA, Brown D, Mor G. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Mol Cancer Ther, 2016; 15(6):1279-90.

11. Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurrea-Soteras M, Sumi N, Alvero AB, Glackin C, and Mor G. p53-Pirh2 complex promotes Twist1 degradation and inhibits EMT in ovarian cancer cells. Mol Cancer Res, 2019; 
17(1):153-164.

12. Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene, 2015; 34(27):3605-16.

13. Yang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, Mor G. Detection of p53 protein transcriptional activity by chromatin immunoprecipitation. Methods Mol Biol,, 2015; 1219:87-93.

14. Yang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, Mor G. Detection of p53 protein aggregation in cancer cell lines and tumor